iiinova — where your digital self keeps evolving

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 11/09/2026

🔬 Pleased to share our new collaborative paper in @bloodjournals.hematology.org on frontline blinatumomab in childhood B-ALL! Chemo-era risk factors did not predict relapse. Instead, early Cycle 1 MRD response and genetics (IKZF1plus, DUX4-r) defined risk. Read more📖 doi.org/10.1182/bloo...

021

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 29/04/2026

First-ever in-person PPI panel meeting for @lrcg.bsky.social @newcastleuni.bsky.social Great discussions with patients & families on ALL risk, AI in treatment, & reducing therapy. Lab tour highlight: lab coats on & excitement all around Part of BIOINFORM — @cancerresearchuk.org #Research #ALL

010

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 27/03/2026

At #𝐈𝐂𝐊𝐒𝐇2026 in Seoul!🩸 @avmoorman.bsky.social is presenting on integrating Genetics & MRD in Acute Lymphoblastic Leukaemia🧬 🎯 Goal: Subtype-specific MRD thresholds to reduce over-treatment. 🚀 Future: Flexible risk algorithms to support novel therapies. #Leukaemia #PrecisionMedicine #Hematology

As an invited speaker at the 2026 𝐊𝐨𝐫𝐞𝐚𝐧 𝐒𝐨𝐜𝐢𝐞𝐭𝐲 𝐨𝐟 𝐇𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐂𝐊𝐒𝐇2026), 𝐏𝐫𝐨𝐟. Anthony Moorman shared insights on the "𝑰𝒏𝒕𝒆𝒈𝒓𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝑴𝑹𝑫 𝒂𝒏𝒅 𝑮𝒆𝒏𝒆𝒕𝒊𝒄𝒔 𝒂𝒔 𝒂 𝑻𝒉𝒆𝒓𝒂𝒑𝒆𝒖𝒕𝒊𝒄 𝑮𝒖𝒊𝒅𝒆𝒑𝒐𝒔𝒕 𝒊𝒏 𝑨𝑳𝑳".🧬

The presentation focused on a critical shift in precision medicine:
🩸𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐒𝐭𝐫𝐚𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧: Moving beyond a "one-size-fits-all" approach by using subtype-specific Minimal Residual Disease (MRD) thresholds to guide therapy.
🩸𝐑𝐞𝐝𝐮𝐜𝐢𝐧𝐠 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲: Shifting the focus toward identifying patients who can be cured with less intensive chemotherapy.
🩸𝐅𝐮𝐭𝐮𝐫𝐞-𝐏𝐫𝐨𝐨𝐟𝐢𝐧𝐠: Designing flexible risk algorithms that incorporate novel therapies like immunotherapy.

By combining genomic data with treatment response, we are moving closer to a future where therapy is perfectly tailored to every patient.🏥

020

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 27/03/2026

Proud to see @lrcg.bsky.social contribute to this global study in @nature.com(𝘕𝘢𝘵. 𝘊𝘰𝘮𝘮𝘶𝘯). We shared data to help refine AI that predicts leukemia subtypes from routine lab results, aiming to close global health diagnostic gaps🩸🌍 Read: doi.org/10.1038/s414... #Leukemia #AI #NewcastleUni

Turki, A.T., Fan, Y., Hernández-Sánchez, A. et al. International testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data. Nat Commun 17, 2649 (2026). https://doi.org/10.1038/s41467-026-70584-z

010

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 16/03/2026

Great to be at the Annual Conference of @cclguk.bsky.social in Manchester. Prof. @avmoorman.bsky.social shared how the VIVO Biobank supports acute leukaemia research, highlighting key research from @lrcg.bsky.social, including the UKALL CNA profile in the ALLTogether trial.🧬🤝

Prof. Anthony Moorman presenting at the CCLG Annual Conference in Manchester, discussing how the VIVO Biobank and research from the Leukaemia Research Cytogenetics Group support advances in acute leukaemia research.

032

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 13/03/2026

𝑯𝒊𝒈𝒉𝒍𝒊𝒈𝒉𝒕𝒊𝒏𝒈 𝑩-𝒄𝒆𝒍𝒍 𝑨𝒄𝒖𝒕𝒆 𝑳𝒚𝒎𝒑𝒉𝒐𝒃𝒍𝒂𝒔𝒕𝒊𝒄 𝑳𝒆𝒖𝒌𝒂𝒆𝒎𝒊𝒂 (𝑩-𝑨𝑳𝑳) 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉🧬 Our group lead @avmoorman.bsky.social presented on risk stratification in B-ALL at the International ALL Assembly, sponsored by @amgen.bsky.social. Great opportunity to share our work with the international research community.

The talk focused on risk stratification in 𝑩-𝒄𝒆𝒍𝒍 𝑨𝒄𝒖𝒕𝒆 𝑳𝒚𝒎𝒑𝒉𝒐𝒃𝒍𝒂𝒔𝒕𝒊𝒄 𝑳𝒆𝒖𝒌𝒂𝒆𝒎𝒊𝒂 (𝑩-𝑨𝑳𝑳), emphasizing the role of cytogenetic approaches in identifying patient risk profiles and guiding treatment strategies🔬📊.

011

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 22/12/2025

Excited to share our evaluation of the TALLSorts classifier!🧬 Our research letter validates its utility against standard DNA methods for paediatric T-ALL, demonstrating high concordance✅ Published now in British Journal of Haematology @wiley.com. Read here: onlinelibrary.wiley.com/doi/10.1111/...

040

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 02/12/2025

Sharing a great 𝐏𝐡𝐃 𝐒𝐭𝐮𝐝𝐞𝐧𝐭𝐬𝐡𝐢𝐩 opportunity in 𝐁𝐢𝐨𝐬𝐞𝐧𝐬𝐨𝐫 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐟𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠. This multidisciplinary project focuses on developing next-generation biosensors for cancer monitoring and offers full funding for up to four years. Click for more information: www.ncl.ac.uk/postgraduate...

ncl.ac.uk

Search for Postgraduate Scholarships and Other Funding

Search scholarships and funding for postgraduate study at Newcastle University. Find financial support tailored to your course and eligibility.

010

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 06/11/2025

We’re proud to see our Prof Christine Harrison featured speaking with His Royal Highness The Duke of Kent during one of his visits to @newcastleuni.bsky.social. We join @bloodcanceruk.bsky.social in wishing His Royal Highness a very happy 90th birthday 🎉🎂 and thanking him for his support.

031

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 05/11/2025

Last month in Madrid, the ALLTogether1 trial brought Europe’s teams roundtable. @avmoorman.bsky.social and other LRCG members shared genetics work to sort risk better and tailor treatment in ALL. Days like this remind us: good collaboration turns into patient impact. @newcastleuni.bsky.social

040

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 05/11/2025

From the North East: a cancer survivor who became a doctor - proof that resilience + research change lives. With CRUK’s £4.1m boost to @newcastleuni.bsky.social, LRCG is excited to turn hope into outcomes. To the individual: your courage lifts us all. Read at www.chroniclelive.co.uk/news/north-e...

chroniclelive.co.uk

Lad diagnosed with cancer at 14 achieves dream of becoming doctor

Cramlington-born Dan Mattison has become a doctor - fulfilling an ambition he has had since a teenage cancer diagnosis

020

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 31/10/2025

BIOINFORM (£2.7m @crukpolicy.bsky.social project) will: build CRISTAL (shared clinical/genomic data portal), develop AI risk tools to guide therapy, study new genetic changes in ALL, and map the genomics of childhood AML — so each patient gets the most effective, least toxic treatment.

030

Leukaemia Research Cytogenomics Group (LRCG) @lrcg.bsky.social · 31/10/2025

Exciting milestone as we held BIOINFORM project kick-off at @newcastleuni.bsky.social, funded by @crukpolicy.bsky.social. The day began with presentations tracing the history of LRCG and introducing the different work packages that will drive the BIOINFORM project forward. @avmoorman.bsky.social

020